Indoor Tanning Bed Restrictions and more in the December FDA Women's Health Update

["FDA Office of Women's Health" <fda@xxxxxxxxxxxxxxxxxxxxxxx>]

Title: Indoor Tanning Bed Restrictions and more in the December FDA Women's Health Update

December 2015
www.fda.gov/womens

Message from the Director

As we closeout another year, FDA continues to work to protect the public’s health by proposing new rules on indoor tanning beds and educating health professionals and the general public about product safety. Check out this final update for 2015 and look to us in the New Year for exciting new activities and resources on clinical trials, pregnancy and more.

Marsha Henderson, Assistant Commissioner for Women’s Health

FDA women's health Highlights

FDA Proposes Tanning Bed Age Restrictions and Other Important Safety Measures

Indoor tanning is a known contributor to skin cancer, including melanoma (its most deadly form), and other skin damage. On December 18, the FDA issued two proposed rules ‎to protect public health by preventing the use of sunlamp products (also commonly known as indoor tanning beds) by minors and reducing the risk of using these devices for adults.

The first proposed rule would restrict use of sunlamp products to individuals 18 and older. In addition, before their first tanning session and every six months thereafter, adult users over age 18 would have to sign a risk acknowledgement certification that states that they have been informed of the risks to health that may result from use of sunlamp products. A second proposed rule would require that sunlamp manufacturers and tanning facilities take additional measures to improve the overall safety of these devices.

Learn more about the proposed rules.

New MQSA Insights on Mammography

The Mammography Quality Standards Act’s (MQSA) program posts MQSA Insights articles to provide information about national inspection results and frequently-requested national statistical data for the general public, press, researchers, and healthcare providers. The goal of the MQSA Insights is to help facilities improve the quality of mammography by allowing them to see how facilities as an aggregate are doing across the nation as well as through exploring specific mammography topics. Read the latest MQSA Insights

WebMD Interview on Cosmetics

As a part of their Expert Q&A series, WebMD talked with Linda Katz, MD, the director of the FDA’s Office of Cosmetics and Colors, on the safety of beauty products. The interview highlighted what FDA does to protect consumers from unsafe cosmetics and how women can report serious problems caused by cosmetic products. Expert QA: Are Your Beauty Products Safe? How to Report a Cosmetic-Related Problem

Extras

FDA launches precisionFDA

FDA recently launched precisionFDA, an online, cloud-based, portal that will allow scientists from industry, academia, government and other partners to come together to foster innovation and develop the science behind a method of “reading” DNA known as next-generation sequencing (or NGS). PrecisionFDA provides the genomics community with a secure platform where participants can access and share datasets, analysis pipelines, and bioinformatics tools, in order to benchmark their approaches and advance regulatory science.

Learn more about precisionFDA

FDA Meetings

Public Workshop –Devices for Monitoring Warfarin Therapy

January 25, 2016 - FDA White Oak Campus, Silver Spring, MD

 

Please share this update with your network, members, constituents, and community

FDA Office of Women's Health
10903 New Hampshire Avenue
WO32 - Room 2333
Silver Spring, MD 20993*0002
301-796-9440

---

Subscriber Services:
Manage Preferences  |  Unsubscribe  |  Help with this service

Stay Connected:

---

This email was sent to list-fda@xxxxxxxxxxx using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420